Medpace Holdings, Inc. ranks in an above-average position in its peer group, with stability as the least supportive dimension. The trend is mixed and momentum is weakening.
Peer-relative scores, weakest to strongest
Medpace Holdings, Inc. is a clinical research organization offering comprehensive clinical trial services to the pharmaceutical and biotechnology industries.
MEDP is seen as a reliable growth leader commanding a premium, combining a sector-leading operating margin of 27.5% (well above the CRO peer median) with above-average CRO growth and proactive guidance. The market reads every guidance raise as confirmation of its outperformance story—yet a 1Y volatility of 41.8% (high for sector leaders) shows how quickly sentiment can change. Because investors price MEDP on sustained growth rather than just current results, any break in outlook or missed guidance leads to swift premium compression. In this setup, a single weak growth quarter or missed guidance can erase the premium quickly, as the market is unforgiving when MEDP's outperformance narrative falters.
Break down MEDP's position across all dimensions with the full interactive tool.
This analysis is rule-based and descriptive. Peer-relative scores are derived from functional peer group comparisons using publicly available financial data. Scores reflect structural positioning only and do not constitute investment advice, a buy or sell recommendation, or a forecast of future performance. AssetNext peer scores are recalculated periodically as new data becomes available.
AssetNext scores reflect each company's structural position within its functional peer group — not a ranking against all stocks simultaneously. Peers are identified by similarity across eight financial dimensions, including revenue growth trajectory, margin structure, capital intensity, and earnings stability. A score of 75 means the company ranks in the top quartile within its own peer group, not the entire market.
Four dimension scores drive the overall peer score: Growth (revenue trajectory and expansion dynamics), Quality (margin structure and capital efficiency), Valuation (peer-relative pricing on standard multiples), and Stability (earnings consistency and financial predictability). Each dimension is scored 0–100 relative to the peer group, then combined into an overall peer score using equal weighting.
Because scores are peer-relative, the same company can have slightly different scores in different index universes. On comparison pages, both companies are shown within their shared peer universe wherever possible — so the scores are directly comparable. The peer basis is stated on each score card.
Scores are recalculated periodically as underlying financial data is updated. All analysis is descriptive and rule-based — AssetNext describes structural realities and never issues buy, sell or hold recommendations.